851008-74-7

Upstream product

• 7205-60-9 1-(ethylsulfanyl)-4-nitrobenzene 
• 1849-36-1 para-nitrobenzenethiol 
• 7205-70-1 (R,S)-1-(ethylsulfinyl)-4-nitrobenzene 

Downstream Products

• 1173911-14-2 C₉H₁₂N₂O₃S 
• 1173911-05-1 C₉H₁₂N₂O₃S 
• 851008-62-3 (R,S)-N-(ethoxycarbonyl)-S-ethyl-S-(4-nitrophenyl)sulfoximide 
• 1223498-39-2 (R,S)-S-[4-({5-bromo-4-[(1R,2R)-(2-hydroxy-1-methylpropyl)amino]pyrimidin-2-yl}amino)phenyl]-S-ethylsulfoximide 
• 851007-68-6 (R,S)-S-[4-({5-bromo-4-[(1R,2R)-(2-hydroxy-1-methylpropyl)amino]pyrimidin-2-yl}amino)phenyl]-N-(ethoxycarbonyl)-S-ethylsulfoximide 
• 1223498-83-6 C₁₈H₂₄F₃N₅O₂S 
• 1223498-82-5 C₁₈H₂₄F₃N₅O₂S 
• 1223498-81-4 C₁₇H₂₂F₃N₅O₂S 
• 1223498-78-9 C₁₇H₂₂F₃N₅O₂S 
• 1223498-63-2 (R,S)-S-(4-aminophenyl)-S-ethyl-N-(trifluoroacetyl)sulfoximide 

Relevant academic research and scientific papers

The lab oddity prevails: Discovery of Pan-CDK inhibitor (R)-S-Cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide (BAY1000394) for the treatment of cancer

Lead optimization of a high-throughput screening hit led to the rapid identification of aminopyrimidine ZK304709, a multitargeted CDK and VEGF-R inhibitor that displayed a promising preclinical profile. Nevertheless, ZK304709 failed in phaseI studies due

SULFOXIMINE-SUBSTITUTED ANILINOPYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THE PRODUCTION THEREOF, AND USE AS MEDICINE

The invention relates to sulfoximine-substituted anilino-pyrimidine derivatives of formula (I). methods of production thereof, and use thereof as medication for the treatment of various diseases.

Sulfoximine-substituted trifluoromethylpyrimidine analogs as inhibitors of proline-rich tyrosine kinase 2 (PYK2) show reduced hERG activity

The synthesis, in vitro properties, and in vivo pharmacokinetics for a series of sulfoximine-substituted trifluoromethylpyrimidines as inhibitors of proline-rich tyrosine kinase, a target for the possible treatment of osteoporosis, are described. These co

ALKYNYLPYRIMIDINES AS TIE2 KINASE INHIBITORS

The invention relates to alkynylpyrimidines according to the general formula (I) in which A, R1, R2, R3, R4, R5, and R6 are as defined in the claims, to pharmaceutical compositions comprising said alkynylpyrimidines, to methods of preparing said alkynylpyrimidines, as well as to uses thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with Tie2 and VEGFR2 signalling.

SULFOXIMINE-SUBSTITUTED PYRIMIDINES , THEIR PREPARATION AND USE AS DRUGS

The invention relates to sulfoximine-substituted pyrimidines of the general Formula (I) processes for the preparation thereof and their use as kinase inhibitors for treating for example cancer or inflammation.

Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs

The invention relates to sulfoximine-substituted pyrimidines of the general formula I processes for the preparation thereof and their use as drugs.